Outcome of children with high-risk neyroblastoma treated with autologous stem cell transplantation /
Mahmoud Hammad Mahmoud
Outcome of children with high-risk neyroblastoma treated with autologous stem cell transplantation / نتائج علاج الأطفال المصابين بأورام العقد العصبية (النيوروبلاستوما) عالية الخطورة بزراعة النخاع العظمى الذاتى Mahmoud Hammad Mahmoud ; Supervised Mohamed Hany Mohamed Hussein , Alaa Mohamed Elhaddad , Wael Zekri Khaled - Cairo : Mahmoud Hammad Mahmoud , 2013 - 139 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
To analyze the outcome and to identify risk factors associated with transplant outcome regarding the stage of disease and pre-transplant disease status (complete remission, very good partial remission and partial remission). Two years follow up of 51 pediatric patients with high-risk neuroblastoma treated with a multimodal schedule and received HDC with busulfan and melphalan as a our standard conditioning regimen
Autologous transplantation Busulfan and melphalan High risk neuroblastoma
Outcome of children with high-risk neyroblastoma treated with autologous stem cell transplantation / نتائج علاج الأطفال المصابين بأورام العقد العصبية (النيوروبلاستوما) عالية الخطورة بزراعة النخاع العظمى الذاتى Mahmoud Hammad Mahmoud ; Supervised Mohamed Hany Mohamed Hussein , Alaa Mohamed Elhaddad , Wael Zekri Khaled - Cairo : Mahmoud Hammad Mahmoud , 2013 - 139 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
To analyze the outcome and to identify risk factors associated with transplant outcome regarding the stage of disease and pre-transplant disease status (complete remission, very good partial remission and partial remission). Two years follow up of 51 pediatric patients with high-risk neuroblastoma treated with a multimodal schedule and received HDC with busulfan and melphalan as a our standard conditioning regimen
Autologous transplantation Busulfan and melphalan High risk neuroblastoma